Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

@article{Munster2009ClinicalAB,
  title={Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC},
  author={P. Munster and D. Marchion and E. Biçaku and M. Lacevic and J. Kim and B. Centeno and A. Daud and Anthony M Neuger and S. Minton and D. Sullivan},
  journal={Clinical Cancer Research},
  year={2009},
  volume={15},
  pages={2488 - 2496}
}
  • P. Munster, D. Marchion, +7 authors D. Sullivan
  • Published 2009
  • Biology, Medicine
  • Clinical Cancer Research
    • Purpose: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. Experimental Design: A phase I dose escalation of valproic acid given on days 1 to 3 followed by epirubicin (day 3) was followed by a dose expansion of valproic acid combined with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC100). Pharmacodynamic and pharmacokinetic studies entailed valproic acid and epirubicin plasma… CONTINUE READING
    View on AACR
    clincancerres.aacrjournals.org
    134 Citations
    Highly Influencial Citations
    6
    Background Citations
    44
    Methods Citations
    13
    Results Citations
    7
    134 Citations
    Citation Type

    Citation Type

    Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer
    • 21
    • PDF
    Cancer esearch cer Therapy : Preclinical se I Pharmacokinetic and Pharmacodynamic Evaluation ombined Valproic Acid / Doxorubicin Treatment in Dogs R Spontaneous Cancer
    • PDF
    Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
    • 138
    A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
    • 16
    Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    • R. Aggarwal, S. Thomas, +11 authors P. Munster
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2017
    • 40
    Spontaneous Cancer
    • PDF
    Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    • 36
    A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    • 279
    • PDF
    Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
    • 28
    A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
    • 104

    References

    SHOWING 1-10 OF 76 REFERENCES
    Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    • P. Münster, D. Marchion, +11 authors A. Daud
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2007
    • 198
    Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
    • 169
    • PDF
    Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
    • 124
    Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
    • O. O’Connor, M. Heaney, +12 authors W. Kelly
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2006
    • 403
    Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
    • 166
    • PDF
    In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
    • 72
    • PDF
    A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
    • 293
    • PDF
    Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
    • 256
    A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
    • 141
    • PDF
    Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    • 155